PF-06260414

PF-06260414 is a selective androgen receptor modulator (SARM) developed by Pfizer for the treatment of muscle weakening conditions such as cachexia. As a SARM, it acts on the androgen receptor to promote anabolic effects on muscle and bone with reduced androgenic activity compared to traditional steroidal androgens. The drug was investigated primarily for its potential in treating conditions associated with muscle loss or weakness, including cachexia and other hormone-related disorders. Clinical studies have shown that it is orally bioavailable and well tolerated in healthy subjects[1][3][5][6]. Development was discontinued after phase I trials[7].

Other names

(R)-6-(4-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl)isoquinoline-1-carbonitrileUNII 3I487UHH95UNII3I487UHH95UNII-3I487UHH95CAS 1612755-71-1CAS1612755-71-1CAS-1612755-71-1